Sentences with phrase «with tumor antigens»

«Some approaches to creating cancer vaccines begin by extracting a patient's own immune cells, priming them with tumor antigens and returning them to the patient, a process that is complex and expensive,» says Mark Poznansky, MD, PhD, director of the MGH Vaccine and Immunotherapy Center and senior author of the report.

High frequency of anti-tumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.

The CNIC research team generated cytotoxic memory T cells specifically targeting cancer by using different methods for vaccination with tumor antigens.

The light - sensitive cells and nanoparticles, called opto - CRAC, were then delivered with the tumor antigen surrogate ovalbumin to mice with melanoma tumors in their lymph nodes to see if an immune response could be activated to target cancer cells.

In a 2009 paper published in Nature Materials, Mooney demonstrated that this could be achieved by loading a porous scaffold — about the size of a dime — with tumor antigen as well as a combination of biological and chemical components meant to attract and activate dendritic cells.

Not exact matches

Many tumors release cells with distinctive antigens on their surfaces, and affinity - based techniques can pull these cells out of the blood sample relatively easily.

Another version, the CTC - iChip, rapidly isolates CTCs in a way that does not rely on preidentified tumor antigens, allowing capture of cells with gene expression patterns that may be missed by the antibodies used in the HBCTC - Chip.

In collaboration with the group of Valerian Kagan, Ph.D., D.Sc., at the University of Pittsburgh, Gabrilovich and colleagues analyzed in great detail the events that take place in the DCs from tumor - bearing mice models and found that impaired cross-presentation, which occurred in the presence of tumor - derived factors, was associated with defective trafficking of the antigen - MHC complex to the cell surface.

More and more men who believe they have low - risk prostate cancers are opting for active surveillance, forgoing treatment and monitoring the cancer closely with prostate - specific antigen (PSA) tests, digital rectal exams and ultrasounds at regular intervals to see if their tumors are growing.

Compared to a bolus injection containing the same drugs and antigens (but no scaffold), the 3D vaccine was more effective at preventing tumor growth, with 90 % of mice receiving the 3D vaccine still alive at 30 days compared with only 60 % of mice given the bolus injection.

Chimeric antigen receptor (CAR) T cell therapy, which edits a cancer patient's T cells to recognize their tumors, has successfully helped patients with aggressive blood cancers but has yet to show the ability to treat solid tumors.

In the featured article of The Journal of Nuclear Medicine's October issue, German researchers report on their recent clinical experience, which establishes a dosing regimen for actinium - 225 (225Ac)- labeled targeted alpha therapy of patients with prostate specific membrane antigen (PSMA)- positive tumors.

We report here the adoptive transfer, to patients with metastatic melanoma, of highly selected tumor - reactive T cells directed against overexpressed self - derived differentiation antigens after a nonmyeloablative conditioning regimen.

Allison JP, McIntyre BW, Bloch D. Tumor - specific antigen of murine T - lymphoma defined with monoclonal antibody.

The symposium features presentations by Philippa Marrack and John Kappler talking on the T cell repertoire; William Paul on interleukin 4 as a prototypic immunoregulatory cytokine; Timothy Springer on lymphocyte trafficking; Pamela Bjorkman on structural studies of MHC and MHC - related proteins, and Jack Strominger on peptide presentation by class I and II MHC proteins; Thierry Boon on genes coding for tumor rejection antigens, including the first tumor antigen, MAGE - 1; and Philip Greenberg on the modification of T cells for adoptive therapy by retroviral - mediated gene insertion Since then, the symposia series has attracted leading immunologists in the cancer vaccine and antibody fields, providing them with a comprehensive view of the promises and challenges in the development of cancer immunotherapies.

Steven A. Rosenberg and colleagues at the Surgery Branch of the National Cancer Institute demonstrate that adoptive immunotherapy with CD8 + T cells genetically engineering to recognize the NY - ESO - 1 antigen could induce significant tumor regressions in patients with metastatic synovial sarcoma and melanoma.

(PMID: 15657293) Download PDF Lurquin C, Lethé B, Corbière V, Théate I, van Baren N, Coulie PG, Boon T. Contrasting frequencies of anti-tumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen.

Alex Huang and Drew Pardoll, with Elizabeth Jaffee and Hyam Levitsky at Johns Hopkins School of Medicine demonstrate tumor - associated antigen processing and presentation to CD8 + T cell by bone marrow - derived professional antigen presenting cells via «cross-priming.»

Bone marrow - derived mesenchymal stem cells undergo JCV T - antigen mediated transformation and generate tumors with neuroectodermal characteristics.

While much recent research has not been published in this area, there is actually a long history of studies that show: (1) there is a significant number of antigens shared between tumors and embryonic tissues (called «oncofetal antigens») and, consequently, antibodies made against tumors can also recognize embryonic tissues, and vice versa; (2) pregnancy confers some immunity against cancer (accompanied by antibody production against oncofetal antigens), not only against its occurrence but also against its growth; (3) similar to pregnancy, an immune response against cancer can be generated by vaccinating animals with embryonic tissues.

Using a combination of biochemical and genetic approaches, Darnell's lab discovered that the immune systems of PND patients thwart tumors with what is essentially an antiviral response: The patients» T cells produce CD8 + killer T cells that recognize the neuronal antigens present within their tumors.

Although they have distinct mechanisms of action, the lead agents from both platforms — CMB305 and G100 — where designed to convert «cold» tumors, or those without CTLs, to «hot» tumors, or those with CTLs specific for the antigens expressed by the tumor.

Treatment with HSV1 - TK is expected to kill transduced brain cells, thus exposing tumor antigen.

Trautmann L, Labarrière N, Jotereau F, Karanikas V, Gervois N, Connerotte T, Coulie P, Bonneville M. Dominant TCR Va usage by virus and tumor reactive T cells with wide affinity ranges for their specific antigens.

The trick with subtractive immunization is to first tolerize an organism - with a non-metastatic tumor cell, using an immune suppressant chemical like cyclophosphamide to kill off all the immune cells that recognize the immunodominant antigens.

This novel vaccine encodes the tumor antigen TERT, which is highly expressed in tumor cells, and is particularly high in tumor samples from patients with mutations in DNA damage repair pathways, such as the BRCA1 / BRCA2 pathway.

Low - dose chemotherapy, radiation, or targeted therapies given in combination with immune checkpoint blockade may prove to be an effective and efficient way to immunize the body against tumor cells,» says CRI Scientific Advisory Council associate director James P. Allison, Ph.D., who identified the first immune checkpoint blockade with his discovery in 1995 that the cytotoxic T lymphocyte antigen - 4 (CTLA - 4) receptor inhibited T cell responses.

In melanoma, an increase in overall mutational and neoantigen load — novel tumor - specific antigens that can be recognized by the immune system — was associated with clinical benefit from checkpoint blockade.

SAN DIEGO, March 28, 2017 (GLOBE NEWSWIRE)-- Invivoscribe ® Technologies Inc., a global company with decades of experience providing internationally standardized clonality and biomarker testing solutions for the fields of oncology, personalized molecular diagnostics ®, and personalized molecular medicine ®, reports that its next - generation sequencing (NGS) LymphoTrack ® Assay kits are being used by its LabPMM ® clinical laboratories, pharmaceutical partners, and cancer centers to identify and monitor chimeric antigen receptor T - cells (CAR - T) and engineered T - cell receptors in peripheral blood of subjects in support of immuno - therapeutic drug development and treatment regimen development for both hematologic and solid tumors.

As noted above, existing cancer vaccines that use dendritic cells require extracting cells from a patient's blood, treating them with an engineered protein or nucleic acid that combines tumor antigens with immune - stimulating molecules, and returning the activated dendritic cells to the patient.

We believe that when G100 is administered with mechanisms that kill, or lyse, tumor cells (such as radiation), it may cause dendritic cells near the lysed tumor to activate and capture the wide range of released endogenous tumor antigens.

They compete with candida in the intestine, they suppress the growth of potentially harmful bacteria, they produce substances that can lower cholesterol, they enhance the protective barrier of the digestive tract, they help produce vitamin K, they improve immune function, they lower blood cholesterol in some people, they lower blood pressure in some people, they aid in the digestion of lactose, they prevent cavities, they decrease the passage of bacteria or antigens from the intestines to the blood stream, they fight pre-carcinogenic or mutagenic compounds, they lower the pH of intestinal contents, they utilize oxalate (oxalate contributes to kidney stones), they detoxify ingested carcinogens, they produce compounds that inhibit the growth of tumor cells, and more!

LEUKOCELL 2 is a multiple viral antigen vaccine for vaccination of healthy cats 9 weeks of age or older as an aid in preventing persistent viremia, lymphoid tumors caused by feline leukemia virus (FeLV) and diseases associated with FeLV infection.

These results suggest that tumor antigen loaded CD40 - B may serve as a practical alternative to DC in cell - based vaccine strategies for both dogs and humans with cancer.